Trav19: A Potential Drug Target for Immune and Inflammatory Diseases

Target Name: TRAV19

NCBI ID: G28664

TRAV19

Other Name(s): TCRAV12S1 | T cell receptor alpha variable 19 | TCRAV19S1

Trav19: A Potential Drug Target for Immune and Inflammatory Diseases

Trav19 (T-cell receptor alpha chain 19) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the T-cell receptor alpha chain family, which is a subfamily of the T-cell receptor superfamily. This protein plays a role in the immune system and has been identified as a potential drug target in the treatment of various diseases.

The T-cell receptor alpha chain is a family of transmembrane proteins that are involved in the immune response. The chain consists of four subunits: alpha-1, alpha-2, alpha-3, and alpha-4. Each subunit of the T-cell receptor alpha chain contains a unique extracellular domain that is involved in cell-cell and cell-tissue interactions.

Trav19 is a 19kDa protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the T-cell receptor alpha chain family and is involved in the immune response.

One of the unique features of Trav19 is its extracellular domain. The extracellular domain of Trav19 consists of a N-terminal region that is involved in cell-cell and cell-tissue interactions. This region is made up of a unique sequence that is specific to Trav19 and is involved in the regulation of T-cell responses.

In addition to its role in the immune system, Trav19 has also been identified as a potential drug target in the treatment of various diseases. For example, Trav19 has been shown to be involved in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

Furthermore, Trav19 has also been shown to be involved in the regulation of inflammation and has been identified as a potential therapeutic target for the treatment of inflammatory diseases. This is because the extracellular domain of Trav19 contains a unique sequence that is involved in the regulation of inflammation and immune responses.

In conclusion, Trav19 is a protein that is expressed in various tissues of the body and plays a role in the immune system. It is a member of the T-cell receptor alpha chain family and has been identified as a potential drug target for the treatment of various diseases. Further research is needed to fully understand the role of Trav19 in the immune system and its potential as a therapeutic target.

Protein Name: T Cell Receptor Alpha Variable 19

Functions: V region of the variable domain of T cell receptor (TR) alpha chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRAV19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAV19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets